Joseph R. Calabrese, MD

Aripiprazole to Treat Bipolar Disorder

March 29, 2017

Read a randomized control trial evaluating the efficacy and safety of once-monthly long-acting injectable antipsychotic aripiprazole.

Joseph R. Calabrese, Raymond Sanchez, Na Jin, et al

Original Research

Baseline Disability and Poor Functioning in Bipolar Disorder Predict Worse Outcomes: Results From the Bipolar CHOICE Study

January 27, 2016

Thilo Deckersbach, Andrew A. Nierenberg, Melvin G. McInnis, et al

Original Research

Bipolar CHOICE (Clinical Health Outcomes Initiative in Comparative Effectiveness): A Pragmatic 6-Month Trial of Lithium Versus Quetiapine for Bipolar Disorder

January 27, 2016

Andrew A. Nierenberg, Susan L. McElroy, Edward S. Friedman, et al

Consensus Statement

Assessing Cognitive Function in Bipolar Disorder: Challenges and Recommendations for Clinical Trial Design

March 25, 2015

Katherine E. Burdick, Terence A. Ketter, Joseph F. Goldberg, et al

Original Research

Efficacy and Safety of Low- and High-Dose Cariprazine in Acute and Mixed Mania Associated With Bipolar I Disorder: A Double-Blind, Placebo-Controlled Study

November 25, 2014

Joseph R. Calabrese, Anju Starace, Kaifeng Lu, et al

Original Research

Efficacy and Safety of Adjunctive Armodafinil in Adults With Major Depressive Episodes Associated With Bipolar I Disorder: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial

July 22, 2014

Joseph R. Calabrese, Mark A. Frye, Ronghua Yang, et al

Original Research

Quetiapine-XR for Acute Bipolar Depression

June 24, 2014

Read the full study whether Quetiapine-XR is superior to placebo in bipolar I or II depression with GAD and other comorbidities.

Keming Gao, Renrong Wu, David E. Kemp, et al

Original Research

Double-Blind, Randomized, Placebo-Controlled Long-Term Maintenance Study of Aripiprazole in Children With Bipolar Disorder

November 29, 2011

Robert L. Findling, Eric A. Youngstrom, Nora K. McNamara, et al

Original Research

PTSD Comorbidity and Suicidal Ideation Associated With PTSD Within the Ohio Army National Guard

August 15, 2011

Joseph R. Calabrese, Marta Prescott, Marijo Tamburrino, et al

Original Research

Clinical Utility of Early Improvement to Predict Response or Remission in Acute Mania: Focus on Olanzapine and Risperidone

March 8, 2011

David E. Kemp, Ellyn Johnson, Wei V. Wang, et al

Letter to the Editor

Reply to Likelihood to Be Helped or Harmed Can Assist in Clinical Decision-Making

February 15, 2011

Keming Gao, David E. Kemp, Joseph R. Calabrese

Original Research

Number Needed to Treat to Harm for Discontinuation Due to Adverse Events in the Treatment of Bipolar Depression, Major Depressive Disorder, and Generalized Anxiety Disorder With Atypical Antipsychotics

October 19, 2010

Keming Gao, David E. Kemp, Elizabeth Fein, et al

Aripiprazole to Treat Bipolar Disorder

Baseline Disability and Poor Functioning in Bipolar Disorder Predict Worse Outcomes: Results From the Bipolar CHOICE Study

Bipolar CHOICE (Clinical Health Outcomes Initiative in Comparative Effectiveness): A Pragmatic 6-Month Trial of Lithium Versus Quetiapine for Bipolar Disorder

Assessing Cognitive Function in Bipolar Disorder: Challenges and Recommendations for Clinical Trial Design

Efficacy and Safety of Low- and High-Dose Cariprazine in Acute and Mixed Mania Associated With Bipolar I Disorder: A Double-Blind, Placebo-Controlled Study

Efficacy and Safety of Adjunctive Armodafinil in Adults With Major Depressive Episodes Associated With Bipolar I Disorder: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial

Quetiapine-XR for Acute Bipolar Depression

Double-Blind, Randomized, Placebo-Controlled Long-Term Maintenance Study of Aripiprazole in Children With Bipolar Disorder

PTSD Comorbidity and Suicidal Ideation Associated With PTSD Within the Ohio Army National Guard

Clinical Utility of Early Improvement to Predict Response or Remission in Acute Mania: Focus on Olanzapine and Risperidone

Reply to Likelihood to Be Helped or Harmed Can Assist in Clinical Decision-Making

Number Needed to Treat to Harm for Discontinuation Due to Adverse Events in the Treatment of Bipolar Depression, Major Depressive Disorder, and Generalized Anxiety Disorder With Atypical Antipsychotics

ELSEWHERE:

FOLLOW US:

Joseph R. Calabrese, MD

Aripiprazole to Treat Bipolar Disorder

Baseline Disability and Poor Functioning in Bipolar Disorder Predict Worse Outcomes: Results From the Bipolar CHOICE Study

Bipolar CHOICE (Clinical Health Outcomes Initiative in Comparative Effectiveness): A Pragmatic 6-Month Trial of Lithium Versus Quetiapine for Bipolar Disorder

Assessing Cognitive Function in Bipolar Disorder: Challenges and Recommendations for Clinical Trial Design

Efficacy and Safety of Low- and High-Dose Cariprazine in Acute and Mixed Mania Associated With Bipolar I Disorder: A Double-Blind, Placebo-Controlled Study

Efficacy and Safety of Adjunctive Armodafinil in Adults With Major Depressive Episodes Associated With Bipolar I Disorder: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial

Quetiapine-XR for Acute Bipolar Depression

Double-Blind, Randomized, Placebo-Controlled Long-Term Maintenance Study of Aripiprazole in Children With Bipolar Disorder

PTSD Comorbidity and Suicidal Ideation Associated With PTSD Within the Ohio Army National Guard

Clinical Utility of Early Improvement to Predict Response or Remission in Acute Mania: Focus on Olanzapine and Risperidone

Reply to Likelihood to Be Helped or Harmed Can Assist in Clinical Decision-Making

Number Needed to Treat to Harm for Discontinuation Due to Adverse Events in the Treatment of Bipolar Depression, Major Depressive Disorder, and Generalized Anxiety Disorder With Atypical Antipsychotics

Celebrating85 Years

Subscribe to readmore articles

Celebrating
85 Years

Subscribe to read
more articles